Global Antibody-radionuclide Conjugates Supply, Demand and Key Producers, 2023-2029
The global Antibody-radionuclide Conjugates market size is expected to reach $ 3159.3 million by 2029, rising at a market growth of 16.7% CAGR during the forecast period (2023-2029).
The Antibody-radionuclide Conjugates Market is driven by the increasing interest in targeted cancer therapy and the potential of combining monoclonal antibodies with radioactive isotopes to deliver precise treatment. Antibody-radionuclide conjugates offer a highly focused approach to treating cancer by delivering radiation directly to tumor cells, minimizing damage to healthy tissue. As the understanding of cancer biology and immunotherapy advances, and personalized treatment options gain prominence, the demand for these conjugates continues to grow. Innovations in conjugation techniques, radiolabeling methods, and the expansion of the oncology pipeline further contribute to market expansion. However, a significant challenge for this market is the need to address complex drug development processes, optimize safety and efficacy, and navigate regulatory standards while ensuring affordability and accessibility for patients. Overcoming production challenges, minimizing off-target effects, and managing development costs are ongoing hurdles. Additionally, the market faces competition from other cancer therapies and the need for continuous research and development to enhance the efficiency and precision of antibody-radionuclide conjugates. Striking a balance between providing safe, effective, and accessible targeted cancer treatments while addressing scientific and regulatory challenges is essential for the continued growth of the Antibody-radionuclide Conjugates Market.
Antibody-radionuclide Conjugates is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
This report studies the global Antibody-radionuclide Conjugates demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Antibody-radionuclide Conjugates, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Antibody-radionuclide Conjugates that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Antibody-radionuclide Conjugates total market, 2018-2029, (USD Million)
Global Antibody-radionuclide Conjugates total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Antibody-radionuclide Conjugates total market, key domestic companies and share, (USD Million)
Global Antibody-radionuclide Conjugates revenue by player and market share 2018-2023, (USD Million)
Global Antibody-radionuclide Conjugates total market by Type, CAGR, 2018-2029, (USD Million)
Global Antibody-radionuclide Conjugates total market ??, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Antibody-radionuclide Conjugates market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences and Clarity Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Antibody-radionuclide Conjugates market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and ??. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Antibody-radionuclide Conjugates Market, By Region:
1. How big is the global Antibody-radionuclide Conjugates market?
2. What is the demand of the global Antibody-radionuclide Conjugates market?
3. What is the year over year growth of the global Antibody-radionuclide Conjugates market?
4. What is the total value of the global Antibody-radionuclide Conjugates market?
5. Who are the major players in the global Antibody-radionuclide Conjugates market?
The Antibody-radionuclide Conjugates Market is driven by the increasing interest in targeted cancer therapy and the potential of combining monoclonal antibodies with radioactive isotopes to deliver precise treatment. Antibody-radionuclide conjugates offer a highly focused approach to treating cancer by delivering radiation directly to tumor cells, minimizing damage to healthy tissue. As the understanding of cancer biology and immunotherapy advances, and personalized treatment options gain prominence, the demand for these conjugates continues to grow. Innovations in conjugation techniques, radiolabeling methods, and the expansion of the oncology pipeline further contribute to market expansion. However, a significant challenge for this market is the need to address complex drug development processes, optimize safety and efficacy, and navigate regulatory standards while ensuring affordability and accessibility for patients. Overcoming production challenges, minimizing off-target effects, and managing development costs are ongoing hurdles. Additionally, the market faces competition from other cancer therapies and the need for continuous research and development to enhance the efficiency and precision of antibody-radionuclide conjugates. Striking a balance between providing safe, effective, and accessible targeted cancer treatments while addressing scientific and regulatory challenges is essential for the continued growth of the Antibody-radionuclide Conjugates Market.
Antibody-radionuclide Conjugates is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
This report studies the global Antibody-radionuclide Conjugates demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Antibody-radionuclide Conjugates, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Antibody-radionuclide Conjugates that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Antibody-radionuclide Conjugates total market, 2018-2029, (USD Million)
Global Antibody-radionuclide Conjugates total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Antibody-radionuclide Conjugates total market, key domestic companies and share, (USD Million)
Global Antibody-radionuclide Conjugates revenue by player and market share 2018-2023, (USD Million)
Global Antibody-radionuclide Conjugates total market by Type, CAGR, 2018-2029, (USD Million)
Global Antibody-radionuclide Conjugates total market ??, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Antibody-radionuclide Conjugates market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences and Clarity Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Antibody-radionuclide Conjugates market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and ??. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Antibody-radionuclide Conjugates Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Beta-emitting
- Targeted Alpha Therapy
- Solid Tumor
- Non Hodgkin Lymphoma
- Bayer
- Novartis
- Lantheus
- Aurobindo Pharma
- Mundipharma
- China Isotope & Radiation
- Curium Pharmaceuticals
- Gilead Sciences
- Clarity Pharmaceuticals
- Curasight
- Nordic Nanovector
- Philogen
- RadioMedix
- Telix Pharmaceuticals
- Orano Med
- Actinium Pharmaceuticals
- Y-mAbs Therapeutics
- Fusion Pharmaceuticals
1. How big is the global Antibody-radionuclide Conjugates market?
2. What is the demand of the global Antibody-radionuclide Conjugates market?
3. What is the year over year growth of the global Antibody-radionuclide Conjugates market?
4. What is the total value of the global Antibody-radionuclide Conjugates market?
5. Who are the major players in the global Antibody-radionuclide Conjugates market?
1 SUPPLY SUMMARY
1.1 Antibody-radionuclide Conjugates Introduction
1.2 World Antibody-radionuclide Conjugates Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Antibody-radionuclide Conjugates Total Market by Region (by Headquarter Location)
1.3.1 World Antibody-radionuclide Conjugates Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Antibody-radionuclide Conjugates Market Size (2018-2029)
1.3.3 China Antibody-radionuclide Conjugates Market Size (2018-2029)
1.3.4 Europe Antibody-radionuclide Conjugates Market Size (2018-2029)
1.3.5 Japan Antibody-radionuclide Conjugates Market Size (2018-2029)
1.3.6 South Korea Antibody-radionuclide Conjugates Market Size (2018-2029)
1.3.7 ASEAN Antibody-radionuclide Conjugates Market Size (2018-2029)
1.3.8 India Antibody-radionuclide Conjugates Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Antibody-radionuclide Conjugates Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Antibody-radionuclide Conjugates Major Market Trends
2 DEMAND SUMMARY
2.1 World Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.2 World Antibody-radionuclide Conjugates Consumption Value by Region
2.2.1 World Antibody-radionuclide Conjugates Consumption Value by Region (2018-2023)
2.2.2 World Antibody-radionuclide Conjugates Consumption Value Forecast by Region (2024-2029)
2.3 United States Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.4 China Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.5 Europe Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.6 Japan Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.7 South Korea Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.8 ASEAN Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.9 India Antibody-radionuclide Conjugates Consumption Value (2018-2029)
3 WORLD ANTIBODY-RADIONUCLIDE CONJUGATES COMPANIES COMPETITIVE ANALYSIS
3.1 World Antibody-radionuclide Conjugates Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Antibody-radionuclide Conjugates Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Antibody-radionuclide Conjugates in 2022
3.2.3 Global Concentration Ratios (CR8) for Antibody-radionuclide Conjugates in 2022
3.3 Antibody-radionuclide Conjugates Company Evaluation Quadrant
3.4 Antibody-radionuclide Conjugates Market: Overall Company Footprint Analysis
3.4.1 Antibody-radionuclide Conjugates Market: Region Footprint
3.4.2 Antibody-radionuclide Conjugates Market: Company Product Type Footprint
3.4.3 Antibody-radionuclide Conjugates Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Antibody-radionuclide Conjugates Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Antibody-radionuclide Conjugates Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Antibody-radionuclide Conjugates Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Antibody-radionuclide Conjugates Consumption Value Comparison
4.2.1 United States VS China: Antibody-radionuclide Conjugates Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Antibody-radionuclide Conjugates Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Antibody-radionuclide Conjugates Companies and Market Share, 2018-2023
4.3.1 United States Based Antibody-radionuclide Conjugates Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Antibody-radionuclide Conjugates Revenue, (2018-2023)
4.4 China Based Companies Antibody-radionuclide Conjugates Revenue and Market Share, 2018-2023
4.4.1 China Based Antibody-radionuclide Conjugates Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Antibody-radionuclide Conjugates Revenue, (2018-2023)
4.5 Rest of World Based Antibody-radionuclide Conjugates Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Antibody-radionuclide Conjugates Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Antibody-radionuclide Conjugates Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Antibody-radionuclide Conjugates Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Beta-emitting
5.2.2 Targeted Alpha Therapy
5.3 Market Segment by Type
5.3.1 World Antibody-radionuclide Conjugates Market Size by Type (2018-2023)
5.3.2 World Antibody-radionuclide Conjugates Market Size by Type (2024-2029)
5.3.3 World Antibody-radionuclide Conjugates Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS ??
6.1 World Antibody-radionuclide Conjugates Market Size Overview ??: 2018 VS 2022 VS 2029
6.2 Segment Introduction ??
6.2.1 Solid Tumor
6.2.2 Non Hodgkin Lymphoma
6.3 Market Segment ??
6.3.1 World Antibody-radionuclide Conjugates Market Size ?? (2018-2023)
6.3.2 World Antibody-radionuclide Conjugates Market Size ?? (2024-2029)
6.3.3 World Antibody-radionuclide Conjugates Market Size ?? (2018-2029)
7 COMPANY PROFILES
7.1 Bayer
7.1.1 Bayer Details
7.1.2 Bayer Major Business
7.1.3 Bayer Antibody-radionuclide Conjugates Product and Services
7.1.4 Bayer Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Bayer Recent Developments/Updates
7.1.6 Bayer Competitive Strengths & Weaknesses
7.2 Novartis
7.2.1 Novartis Details
7.2.2 Novartis Major Business
7.2.3 Novartis Antibody-radionuclide Conjugates Product and Services
7.2.4 Novartis Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Novartis Recent Developments/Updates
7.2.6 Novartis Competitive Strengths & Weaknesses
7.3 Lantheus
7.3.1 Lantheus Details
7.3.2 Lantheus Major Business
7.3.3 Lantheus Antibody-radionuclide Conjugates Product and Services
7.3.4 Lantheus Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Lantheus Recent Developments/Updates
7.3.6 Lantheus Competitive Strengths & Weaknesses
7.4 Aurobindo Pharma
7.4.1 Aurobindo Pharma Details
7.4.2 Aurobindo Pharma Major Business
7.4.3 Aurobindo Pharma Antibody-radionuclide Conjugates Product and Services
7.4.4 Aurobindo Pharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Aurobindo Pharma Recent Developments/Updates
7.4.6 Aurobindo Pharma Competitive Strengths & Weaknesses
7.5 Mundipharma
7.5.1 Mundipharma Details
7.5.2 Mundipharma Major Business
7.5.3 Mundipharma Antibody-radionuclide Conjugates Product and Services
7.5.4 Mundipharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Mundipharma Recent Developments/Updates
7.5.6 Mundipharma Competitive Strengths & Weaknesses
7.6 China Isotope & Radiation
7.6.1 China Isotope & Radiation Details
7.6.2 China Isotope & Radiation Major Business
7.6.3 China Isotope & Radiation Antibody-radionuclide Conjugates Product and Services
7.6.4 China Isotope & Radiation Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 China Isotope & Radiation Recent Developments/Updates
7.6.6 China Isotope & Radiation Competitive Strengths & Weaknesses
7.7 Curium Pharmaceuticals
7.7.1 Curium Pharmaceuticals Details
7.7.2 Curium Pharmaceuticals Major Business
7.7.3 Curium Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
7.7.4 Curium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Curium Pharmaceuticals Recent Developments/Updates
7.7.6 Curium Pharmaceuticals Competitive Strengths & Weaknesses
7.8 Gilead Sciences
7.8.1 Gilead Sciences Details
7.8.2 Gilead Sciences Major Business
7.8.3 Gilead Sciences Antibody-radionuclide Conjugates Product and Services
7.8.4 Gilead Sciences Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Gilead Sciences Recent Developments/Updates
7.8.6 Gilead Sciences Competitive Strengths & Weaknesses
7.9 Clarity Pharmaceuticals
7.9.1 Clarity Pharmaceuticals Details
7.9.2 Clarity Pharmaceuticals Major Business
7.9.3 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
7.9.4 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Clarity Pharmaceuticals Recent Developments/Updates
7.9.6 Clarity Pharmaceuticals Competitive Strengths & Weaknesses
7.10 Curasight
7.10.1 Curasight Details
7.10.2 Curasight Major Business
7.10.3 Curasight Antibody-radionuclide Conjugates Product and Services
7.10.4 Curasight Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Curasight Recent Developments/Updates
7.10.6 Curasight Competitive Strengths & Weaknesses
7.11 Nordic Nanovector
7.11.1 Nordic Nanovector Details
7.11.2 Nordic Nanovector Major Business
7.11.3 Nordic Nanovector Antibody-radionuclide Conjugates Product and Services
7.11.4 Nordic Nanovector Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Nordic Nanovector Recent Developments/Updates
7.11.6 Nordic Nanovector Competitive Strengths & Weaknesses
7.12 Philogen
7.12.1 Philogen Details
7.12.2 Philogen Major Business
7.12.3 Philogen Antibody-radionuclide Conjugates Product and Services
7.12.4 Philogen Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Philogen Recent Developments/Updates
7.12.6 Philogen Competitive Strengths & Weaknesses
7.13 RadioMedix
7.13.1 RadioMedix Details
7.13.2 RadioMedix Major Business
7.13.3 RadioMedix Antibody-radionuclide Conjugates Product and Services
7.13.4 RadioMedix Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 RadioMedix Recent Developments/Updates
7.13.6 RadioMedix Competitive Strengths & Weaknesses
7.14 Telix Pharmaceuticals
7.14.1 Telix Pharmaceuticals Details
7.14.2 Telix Pharmaceuticals Major Business
7.14.3 Telix Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
7.14.4 Telix Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Telix Pharmaceuticals Recent Developments/Updates
7.14.6 Telix Pharmaceuticals Competitive Strengths & Weaknesses
7.15 Orano Med
7.15.1 Orano Med Details
7.15.2 Orano Med Major Business
7.15.3 Orano Med Antibody-radionuclide Conjugates Product and Services
7.15.4 Orano Med Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Orano Med Recent Developments/Updates
7.15.6 Orano Med Competitive Strengths & Weaknesses
7.16 Actinium Pharmaceuticals
7.16.1 Actinium Pharmaceuticals Details
7.16.2 Actinium Pharmaceuticals Major Business
7.16.3 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
7.16.4 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Actinium Pharmaceuticals Recent Developments/Updates
7.16.6 Actinium Pharmaceuticals Competitive Strengths & Weaknesses
7.17 Y-mAbs Therapeutics
7.17.1 Y-mAbs Therapeutics Details
7.17.2 Y-mAbs Therapeutics Major Business
7.17.3 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product and Services
7.17.4 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Y-mAbs Therapeutics Recent Developments/Updates
7.17.6 Y-mAbs Therapeutics Competitive Strengths & Weaknesses
7.18 Fusion Pharmaceuticals
7.18.1 Fusion Pharmaceuticals Details
7.18.2 Fusion Pharmaceuticals Major Business
7.18.3 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
7.18.4 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Fusion Pharmaceuticals Recent Developments/Updates
7.18.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Antibody-radionuclide Conjugates Industry Chain
8.2 Antibody-radionuclide Conjugates Upstream Analysis
8.3 Antibody-radionuclide Conjugates Midstream Analysis
8.4 Antibody-radionuclide Conjugates Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Antibody-radionuclide Conjugates Introduction
1.2 World Antibody-radionuclide Conjugates Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Antibody-radionuclide Conjugates Total Market by Region (by Headquarter Location)
1.3.1 World Antibody-radionuclide Conjugates Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Antibody-radionuclide Conjugates Market Size (2018-2029)
1.3.3 China Antibody-radionuclide Conjugates Market Size (2018-2029)
1.3.4 Europe Antibody-radionuclide Conjugates Market Size (2018-2029)
1.3.5 Japan Antibody-radionuclide Conjugates Market Size (2018-2029)
1.3.6 South Korea Antibody-radionuclide Conjugates Market Size (2018-2029)
1.3.7 ASEAN Antibody-radionuclide Conjugates Market Size (2018-2029)
1.3.8 India Antibody-radionuclide Conjugates Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Antibody-radionuclide Conjugates Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Antibody-radionuclide Conjugates Major Market Trends
2 DEMAND SUMMARY
2.1 World Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.2 World Antibody-radionuclide Conjugates Consumption Value by Region
2.2.1 World Antibody-radionuclide Conjugates Consumption Value by Region (2018-2023)
2.2.2 World Antibody-radionuclide Conjugates Consumption Value Forecast by Region (2024-2029)
2.3 United States Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.4 China Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.5 Europe Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.6 Japan Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.7 South Korea Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.8 ASEAN Antibody-radionuclide Conjugates Consumption Value (2018-2029)
2.9 India Antibody-radionuclide Conjugates Consumption Value (2018-2029)
3 WORLD ANTIBODY-RADIONUCLIDE CONJUGATES COMPANIES COMPETITIVE ANALYSIS
3.1 World Antibody-radionuclide Conjugates Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Antibody-radionuclide Conjugates Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Antibody-radionuclide Conjugates in 2022
3.2.3 Global Concentration Ratios (CR8) for Antibody-radionuclide Conjugates in 2022
3.3 Antibody-radionuclide Conjugates Company Evaluation Quadrant
3.4 Antibody-radionuclide Conjugates Market: Overall Company Footprint Analysis
3.4.1 Antibody-radionuclide Conjugates Market: Region Footprint
3.4.2 Antibody-radionuclide Conjugates Market: Company Product Type Footprint
3.4.3 Antibody-radionuclide Conjugates Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Antibody-radionuclide Conjugates Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Antibody-radionuclide Conjugates Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Antibody-radionuclide Conjugates Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Antibody-radionuclide Conjugates Consumption Value Comparison
4.2.1 United States VS China: Antibody-radionuclide Conjugates Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Antibody-radionuclide Conjugates Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Antibody-radionuclide Conjugates Companies and Market Share, 2018-2023
4.3.1 United States Based Antibody-radionuclide Conjugates Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Antibody-radionuclide Conjugates Revenue, (2018-2023)
4.4 China Based Companies Antibody-radionuclide Conjugates Revenue and Market Share, 2018-2023
4.4.1 China Based Antibody-radionuclide Conjugates Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Antibody-radionuclide Conjugates Revenue, (2018-2023)
4.5 Rest of World Based Antibody-radionuclide Conjugates Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Antibody-radionuclide Conjugates Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Antibody-radionuclide Conjugates Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Antibody-radionuclide Conjugates Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Beta-emitting
5.2.2 Targeted Alpha Therapy
5.3 Market Segment by Type
5.3.1 World Antibody-radionuclide Conjugates Market Size by Type (2018-2023)
5.3.2 World Antibody-radionuclide Conjugates Market Size by Type (2024-2029)
5.3.3 World Antibody-radionuclide Conjugates Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS ??
6.1 World Antibody-radionuclide Conjugates Market Size Overview ??: 2018 VS 2022 VS 2029
6.2 Segment Introduction ??
6.2.1 Solid Tumor
6.2.2 Non Hodgkin Lymphoma
6.3 Market Segment ??
6.3.1 World Antibody-radionuclide Conjugates Market Size ?? (2018-2023)
6.3.2 World Antibody-radionuclide Conjugates Market Size ?? (2024-2029)
6.3.3 World Antibody-radionuclide Conjugates Market Size ?? (2018-2029)
7 COMPANY PROFILES
7.1 Bayer
7.1.1 Bayer Details
7.1.2 Bayer Major Business
7.1.3 Bayer Antibody-radionuclide Conjugates Product and Services
7.1.4 Bayer Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Bayer Recent Developments/Updates
7.1.6 Bayer Competitive Strengths & Weaknesses
7.2 Novartis
7.2.1 Novartis Details
7.2.2 Novartis Major Business
7.2.3 Novartis Antibody-radionuclide Conjugates Product and Services
7.2.4 Novartis Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Novartis Recent Developments/Updates
7.2.6 Novartis Competitive Strengths & Weaknesses
7.3 Lantheus
7.3.1 Lantheus Details
7.3.2 Lantheus Major Business
7.3.3 Lantheus Antibody-radionuclide Conjugates Product and Services
7.3.4 Lantheus Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Lantheus Recent Developments/Updates
7.3.6 Lantheus Competitive Strengths & Weaknesses
7.4 Aurobindo Pharma
7.4.1 Aurobindo Pharma Details
7.4.2 Aurobindo Pharma Major Business
7.4.3 Aurobindo Pharma Antibody-radionuclide Conjugates Product and Services
7.4.4 Aurobindo Pharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Aurobindo Pharma Recent Developments/Updates
7.4.6 Aurobindo Pharma Competitive Strengths & Weaknesses
7.5 Mundipharma
7.5.1 Mundipharma Details
7.5.2 Mundipharma Major Business
7.5.3 Mundipharma Antibody-radionuclide Conjugates Product and Services
7.5.4 Mundipharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Mundipharma Recent Developments/Updates
7.5.6 Mundipharma Competitive Strengths & Weaknesses
7.6 China Isotope & Radiation
7.6.1 China Isotope & Radiation Details
7.6.2 China Isotope & Radiation Major Business
7.6.3 China Isotope & Radiation Antibody-radionuclide Conjugates Product and Services
7.6.4 China Isotope & Radiation Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 China Isotope & Radiation Recent Developments/Updates
7.6.6 China Isotope & Radiation Competitive Strengths & Weaknesses
7.7 Curium Pharmaceuticals
7.7.1 Curium Pharmaceuticals Details
7.7.2 Curium Pharmaceuticals Major Business
7.7.3 Curium Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
7.7.4 Curium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Curium Pharmaceuticals Recent Developments/Updates
7.7.6 Curium Pharmaceuticals Competitive Strengths & Weaknesses
7.8 Gilead Sciences
7.8.1 Gilead Sciences Details
7.8.2 Gilead Sciences Major Business
7.8.3 Gilead Sciences Antibody-radionuclide Conjugates Product and Services
7.8.4 Gilead Sciences Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Gilead Sciences Recent Developments/Updates
7.8.6 Gilead Sciences Competitive Strengths & Weaknesses
7.9 Clarity Pharmaceuticals
7.9.1 Clarity Pharmaceuticals Details
7.9.2 Clarity Pharmaceuticals Major Business
7.9.3 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
7.9.4 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Clarity Pharmaceuticals Recent Developments/Updates
7.9.6 Clarity Pharmaceuticals Competitive Strengths & Weaknesses
7.10 Curasight
7.10.1 Curasight Details
7.10.2 Curasight Major Business
7.10.3 Curasight Antibody-radionuclide Conjugates Product and Services
7.10.4 Curasight Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Curasight Recent Developments/Updates
7.10.6 Curasight Competitive Strengths & Weaknesses
7.11 Nordic Nanovector
7.11.1 Nordic Nanovector Details
7.11.2 Nordic Nanovector Major Business
7.11.3 Nordic Nanovector Antibody-radionuclide Conjugates Product and Services
7.11.4 Nordic Nanovector Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Nordic Nanovector Recent Developments/Updates
7.11.6 Nordic Nanovector Competitive Strengths & Weaknesses
7.12 Philogen
7.12.1 Philogen Details
7.12.2 Philogen Major Business
7.12.3 Philogen Antibody-radionuclide Conjugates Product and Services
7.12.4 Philogen Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Philogen Recent Developments/Updates
7.12.6 Philogen Competitive Strengths & Weaknesses
7.13 RadioMedix
7.13.1 RadioMedix Details
7.13.2 RadioMedix Major Business
7.13.3 RadioMedix Antibody-radionuclide Conjugates Product and Services
7.13.4 RadioMedix Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 RadioMedix Recent Developments/Updates
7.13.6 RadioMedix Competitive Strengths & Weaknesses
7.14 Telix Pharmaceuticals
7.14.1 Telix Pharmaceuticals Details
7.14.2 Telix Pharmaceuticals Major Business
7.14.3 Telix Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
7.14.4 Telix Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Telix Pharmaceuticals Recent Developments/Updates
7.14.6 Telix Pharmaceuticals Competitive Strengths & Weaknesses
7.15 Orano Med
7.15.1 Orano Med Details
7.15.2 Orano Med Major Business
7.15.3 Orano Med Antibody-radionuclide Conjugates Product and Services
7.15.4 Orano Med Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Orano Med Recent Developments/Updates
7.15.6 Orano Med Competitive Strengths & Weaknesses
7.16 Actinium Pharmaceuticals
7.16.1 Actinium Pharmaceuticals Details
7.16.2 Actinium Pharmaceuticals Major Business
7.16.3 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
7.16.4 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Actinium Pharmaceuticals Recent Developments/Updates
7.16.6 Actinium Pharmaceuticals Competitive Strengths & Weaknesses
7.17 Y-mAbs Therapeutics
7.17.1 Y-mAbs Therapeutics Details
7.17.2 Y-mAbs Therapeutics Major Business
7.17.3 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product and Services
7.17.4 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Y-mAbs Therapeutics Recent Developments/Updates
7.17.6 Y-mAbs Therapeutics Competitive Strengths & Weaknesses
7.18 Fusion Pharmaceuticals
7.18.1 Fusion Pharmaceuticals Details
7.18.2 Fusion Pharmaceuticals Major Business
7.18.3 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
7.18.4 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Fusion Pharmaceuticals Recent Developments/Updates
7.18.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Antibody-radionuclide Conjugates Industry Chain
8.2 Antibody-radionuclide Conjugates Upstream Analysis
8.3 Antibody-radionuclide Conjugates Midstream Analysis
8.4 Antibody-radionuclide Conjugates Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Antibody-radionuclide Conjugates Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Antibody-radionuclide Conjugates Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Antibody-radionuclide Conjugates Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Antibody-radionuclide Conjugates Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Antibody-radionuclide Conjugates Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Antibody-radionuclide Conjugates Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Antibody-radionuclide Conjugates Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Antibody-radionuclide Conjugates Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Antibody-radionuclide Conjugates Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Antibody-radionuclide Conjugates Players in 2022
Table 12. World Antibody-radionuclide Conjugates Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Antibody-radionuclide Conjugates Company Evaluation Quadrant
Table 14. Head Office of Key Antibody-radionuclide Conjugates Player
Table 15. Antibody-radionuclide Conjugates Market: Company Product Type Footprint
Table 16. Antibody-radionuclide Conjugates Market: Company Product Application Footprint
Table 17. Antibody-radionuclide Conjugates Mergers & Acquisitions Activity
Table 18. United States VS China Antibody-radionuclide Conjugates Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Antibody-radionuclide Conjugates Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Antibody-radionuclide Conjugates Companies, Headquarters (States, Country)
Table 21. United States Based Companies Antibody-radionuclide Conjugates Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Antibody-radionuclide Conjugates Revenue Market Share (2018-2023)
Table 23. China Based Antibody-radionuclide Conjugates Companies, Headquarters (Province, Country)
Table 24. China Based Companies Antibody-radionuclide Conjugates Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Antibody-radionuclide Conjugates Revenue Market Share (2018-2023)
Table 26. Rest of World Based Antibody-radionuclide Conjugates Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Antibody-radionuclide Conjugates Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Antibody-radionuclide Conjugates Revenue Market Share (2018-2023)
Table 29. World Antibody-radionuclide Conjugates Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Antibody-radionuclide Conjugates Market Size by Type (2018-2023) & (USD Million)
Table 31. World Antibody-radionuclide Conjugates Market Size by Type (2024-2029) & (USD Million)
Table 32. World Antibody-radionuclide Conjugates Market Size ??, (USD Million), 2018 & 2022 & 2029
Table 33. World Antibody-radionuclide Conjugates Market Size ?? (2018-2023) & (USD Million)
Table 34. World Antibody-radionuclide Conjugates Market Size ?? (2024-2029) & (USD Million)
Table 35. Bayer Basic Information, Area Served and Competitors
Table 36. Bayer Major Business
Table 37. Bayer Antibody-radionuclide Conjugates Product and Services
Table 38. Bayer Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Bayer Recent Developments/Updates
Table 40. Bayer Competitive Strengths & Weaknesses
Table 41. Novartis Basic Information, Area Served and Competitors
Table 42. Novartis Major Business
Table 43. Novartis Antibody-radionuclide Conjugates Product and Services
Table 44. Novartis Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Novartis Recent Developments/Updates
Table 46. Novartis Competitive Strengths & Weaknesses
Table 47. Lantheus Basic Information, Area Served and Competitors
Table 48. Lantheus Major Business
Table 49. Lantheus Antibody-radionuclide Conjugates Product and Services
Table 50. Lantheus Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Lantheus Recent Developments/Updates
Table 52. Lantheus Competitive Strengths & Weaknesses
Table 53. Aurobindo Pharma Basic Information, Area Served and Competitors
Table 54. Aurobindo Pharma Major Business
Table 55. Aurobindo Pharma Antibody-radionuclide Conjugates Product and Services
Table 56. Aurobindo Pharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Aurobindo Pharma Recent Developments/Updates
Table 58. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 59. Mundipharma Basic Information, Area Served and Competitors
Table 60. Mundipharma Major Business
Table 61. Mundipharma Antibody-radionuclide Conjugates Product and Services
Table 62. Mundipharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Mundipharma Recent Developments/Updates
Table 64. Mundipharma Competitive Strengths & Weaknesses
Table 65. China Isotope & Radiation Basic Information, Area Served and Competitors
Table 66. China Isotope & Radiation Major Business
Table 67. China Isotope & Radiation Antibody-radionuclide Conjugates Product and Services
Table 68. China Isotope & Radiation Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. China Isotope & Radiation Recent Developments/Updates
Table 70. China Isotope & Radiation Competitive Strengths & Weaknesses
Table 71. Curium Pharmaceuticals Basic Information, Area Served and Competitors
Table 72. Curium Pharmaceuticals Major Business
Table 73. Curium Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
Table 74. Curium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Curium Pharmaceuticals Recent Developments/Updates
Table 76. Curium Pharmaceuticals Competitive Strengths & Weaknesses
Table 77. Gilead Sciences Basic Information, Area Served and Competitors
Table 78. Gilead Sciences Major Business
Table 79. Gilead Sciences Antibody-radionuclide Conjugates Product and Services
Table 80. Gilead Sciences Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Gilead Sciences Recent Developments/Updates
Table 82. Gilead Sciences Competitive Strengths & Weaknesses
Table 83. Clarity Pharmaceuticals Basic Information, Area Served and Competitors
Table 84. Clarity Pharmaceuticals Major Business
Table 85. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
Table 86. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Clarity Pharmaceuticals Recent Developments/Updates
Table 88. Clarity Pharmaceuticals Competitive Strengths & Weaknesses
Table 89. Curasight Basic Information, Area Served and Competitors
Table 90. Curasight Major Business
Table 91. Curasight Antibody-radionuclide Conjugates Product and Services
Table 92. Curasight Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Curasight Recent Developments/Updates
Table 94. Curasight Competitive Strengths & Weaknesses
Table 95. Nordic Nanovector Basic Information, Area Served and Competitors
Table 96. Nordic Nanovector Major Business
Table 97. Nordic Nanovector Antibody-radionuclide Conjugates Product and Services
Table 98. Nordic Nanovector Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Nordic Nanovector Recent Developments/Updates
Table 100. Nordic Nanovector Competitive Strengths & Weaknesses
Table 101. Philogen Basic Information, Area Served and Competitors
Table 102. Philogen Major Business
Table 103. Philogen Antibody-radionuclide Conjugates Product and Services
Table 104. Philogen Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Philogen Recent Developments/Updates
Table 106. Philogen Competitive Strengths & Weaknesses
Table 107. RadioMedix Basic Information, Area Served and Competitors
Table 108. RadioMedix Major Business
Table 109. RadioMedix Antibody-radionuclide Conjugates Product and Services
Table 110. RadioMedix Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. RadioMedix Recent Developments/Updates
Table 112. RadioMedix Competitive Strengths & Weaknesses
Table 113. Telix Pharmaceuticals Basic Information, Area Served and Competitors
Table 114. Telix Pharmaceuticals Major Business
Table 115. Telix Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
Table 116. Telix Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Telix Pharmaceuticals Recent Developments/Updates
Table 118. Telix Pharmaceuticals Competitive Strengths & Weaknesses
Table 119. Orano Med Basic Information, Area Served and Competitors
Table 120. Orano Med Major Business
Table 121. Orano Med Antibody-radionuclide Conjugates Product and Services
Table 122. Orano Med Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Orano Med Recent Developments/Updates
Table 124. Orano Med Competitive Strengths & Weaknesses
Table 125. Actinium Pharmaceuticals Basic Information, Area Served and Competitors
Table 126. Actinium Pharmaceuticals Major Business
Table 127. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
Table 128. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Actinium Pharmaceuticals Recent Developments/Updates
Table 130. Actinium Pharmaceuticals Competitive Strengths & Weaknesses
Table 131. Y-mAbs Therapeutics Basic Information, Area Served and Competitors
Table 132. Y-mAbs Therapeutics Major Business
Table 133. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product and Services
Table 134. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Y-mAbs Therapeutics Recent Developments/Updates
Table 136. Fusion Pharmaceuticals Basic Information, Area Served and Competitors
Table 137. Fusion Pharmaceuticals Major Business
Table 138. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
Table 139. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 140. Global Key Players of Antibody-radionuclide Conjugates Upstream (Raw Materials)
Table 141. Antibody-radionuclide Conjugates Typical Customers
LIST OF FIGURE
Figure 1. Antibody-radionuclide Conjugates Picture
Figure 2. World Antibody-radionuclide Conjugates Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Antibody-radionuclide Conjugates Total Market Size (2018-2029) & (USD Million)
Figure 4. World Antibody-radionuclide Conjugates Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Antibody-radionuclide Conjugates Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 13. Antibody-radionuclide Conjugates Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 16. World Antibody-radionuclide Conjugates Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 18. China Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 23. India Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Antibody-radionuclide Conjugates by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Antibody-radionuclide Conjugates Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Antibody-radionuclide Conjugates Markets in 2022
Figure 27. United States VS China: Antibody-radionuclide Conjugates Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Antibody-radionuclide Conjugates Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Antibody-radionuclide Conjugates Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Antibody-radionuclide Conjugates Market Size Market Share by Type in 2022
Figure 31. Beta-emitting
Figure 32. Targeted Alpha Therapy
Figure 33. World Antibody-radionuclide Conjugates Market Size Market Share by Type (2018-2029)
Figure 34. World Antibody-radionuclide Conjugates Market Size ??, (USD Million), 2018 & 2022 & 2029
Figure 35. World Antibody-radionuclide Conjugates Market Size Market Share ?? in 2022
Figure 36. Solid Tumor
Figure 37. Non Hodgkin Lymphoma
Figure 38. Antibody-radionuclide Conjugates Industrial Chain
Figure 39. Methodology
Figure 40. Research Process and Data Source
Table 1. World Antibody-radionuclide Conjugates Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Antibody-radionuclide Conjugates Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Antibody-radionuclide Conjugates Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Antibody-radionuclide Conjugates Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Antibody-radionuclide Conjugates Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Antibody-radionuclide Conjugates Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Antibody-radionuclide Conjugates Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Antibody-radionuclide Conjugates Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Antibody-radionuclide Conjugates Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Antibody-radionuclide Conjugates Players in 2022
Table 12. World Antibody-radionuclide Conjugates Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Antibody-radionuclide Conjugates Company Evaluation Quadrant
Table 14. Head Office of Key Antibody-radionuclide Conjugates Player
Table 15. Antibody-radionuclide Conjugates Market: Company Product Type Footprint
Table 16. Antibody-radionuclide Conjugates Market: Company Product Application Footprint
Table 17. Antibody-radionuclide Conjugates Mergers & Acquisitions Activity
Table 18. United States VS China Antibody-radionuclide Conjugates Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Antibody-radionuclide Conjugates Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Antibody-radionuclide Conjugates Companies, Headquarters (States, Country)
Table 21. United States Based Companies Antibody-radionuclide Conjugates Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Antibody-radionuclide Conjugates Revenue Market Share (2018-2023)
Table 23. China Based Antibody-radionuclide Conjugates Companies, Headquarters (Province, Country)
Table 24. China Based Companies Antibody-radionuclide Conjugates Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Antibody-radionuclide Conjugates Revenue Market Share (2018-2023)
Table 26. Rest of World Based Antibody-radionuclide Conjugates Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Antibody-radionuclide Conjugates Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Antibody-radionuclide Conjugates Revenue Market Share (2018-2023)
Table 29. World Antibody-radionuclide Conjugates Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Antibody-radionuclide Conjugates Market Size by Type (2018-2023) & (USD Million)
Table 31. World Antibody-radionuclide Conjugates Market Size by Type (2024-2029) & (USD Million)
Table 32. World Antibody-radionuclide Conjugates Market Size ??, (USD Million), 2018 & 2022 & 2029
Table 33. World Antibody-radionuclide Conjugates Market Size ?? (2018-2023) & (USD Million)
Table 34. World Antibody-radionuclide Conjugates Market Size ?? (2024-2029) & (USD Million)
Table 35. Bayer Basic Information, Area Served and Competitors
Table 36. Bayer Major Business
Table 37. Bayer Antibody-radionuclide Conjugates Product and Services
Table 38. Bayer Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Bayer Recent Developments/Updates
Table 40. Bayer Competitive Strengths & Weaknesses
Table 41. Novartis Basic Information, Area Served and Competitors
Table 42. Novartis Major Business
Table 43. Novartis Antibody-radionuclide Conjugates Product and Services
Table 44. Novartis Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Novartis Recent Developments/Updates
Table 46. Novartis Competitive Strengths & Weaknesses
Table 47. Lantheus Basic Information, Area Served and Competitors
Table 48. Lantheus Major Business
Table 49. Lantheus Antibody-radionuclide Conjugates Product and Services
Table 50. Lantheus Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Lantheus Recent Developments/Updates
Table 52. Lantheus Competitive Strengths & Weaknesses
Table 53. Aurobindo Pharma Basic Information, Area Served and Competitors
Table 54. Aurobindo Pharma Major Business
Table 55. Aurobindo Pharma Antibody-radionuclide Conjugates Product and Services
Table 56. Aurobindo Pharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Aurobindo Pharma Recent Developments/Updates
Table 58. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 59. Mundipharma Basic Information, Area Served and Competitors
Table 60. Mundipharma Major Business
Table 61. Mundipharma Antibody-radionuclide Conjugates Product and Services
Table 62. Mundipharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Mundipharma Recent Developments/Updates
Table 64. Mundipharma Competitive Strengths & Weaknesses
Table 65. China Isotope & Radiation Basic Information, Area Served and Competitors
Table 66. China Isotope & Radiation Major Business
Table 67. China Isotope & Radiation Antibody-radionuclide Conjugates Product and Services
Table 68. China Isotope & Radiation Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. China Isotope & Radiation Recent Developments/Updates
Table 70. China Isotope & Radiation Competitive Strengths & Weaknesses
Table 71. Curium Pharmaceuticals Basic Information, Area Served and Competitors
Table 72. Curium Pharmaceuticals Major Business
Table 73. Curium Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
Table 74. Curium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Curium Pharmaceuticals Recent Developments/Updates
Table 76. Curium Pharmaceuticals Competitive Strengths & Weaknesses
Table 77. Gilead Sciences Basic Information, Area Served and Competitors
Table 78. Gilead Sciences Major Business
Table 79. Gilead Sciences Antibody-radionuclide Conjugates Product and Services
Table 80. Gilead Sciences Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Gilead Sciences Recent Developments/Updates
Table 82. Gilead Sciences Competitive Strengths & Weaknesses
Table 83. Clarity Pharmaceuticals Basic Information, Area Served and Competitors
Table 84. Clarity Pharmaceuticals Major Business
Table 85. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
Table 86. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Clarity Pharmaceuticals Recent Developments/Updates
Table 88. Clarity Pharmaceuticals Competitive Strengths & Weaknesses
Table 89. Curasight Basic Information, Area Served and Competitors
Table 90. Curasight Major Business
Table 91. Curasight Antibody-radionuclide Conjugates Product and Services
Table 92. Curasight Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Curasight Recent Developments/Updates
Table 94. Curasight Competitive Strengths & Weaknesses
Table 95. Nordic Nanovector Basic Information, Area Served and Competitors
Table 96. Nordic Nanovector Major Business
Table 97. Nordic Nanovector Antibody-radionuclide Conjugates Product and Services
Table 98. Nordic Nanovector Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Nordic Nanovector Recent Developments/Updates
Table 100. Nordic Nanovector Competitive Strengths & Weaknesses
Table 101. Philogen Basic Information, Area Served and Competitors
Table 102. Philogen Major Business
Table 103. Philogen Antibody-radionuclide Conjugates Product and Services
Table 104. Philogen Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Philogen Recent Developments/Updates
Table 106. Philogen Competitive Strengths & Weaknesses
Table 107. RadioMedix Basic Information, Area Served and Competitors
Table 108. RadioMedix Major Business
Table 109. RadioMedix Antibody-radionuclide Conjugates Product and Services
Table 110. RadioMedix Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. RadioMedix Recent Developments/Updates
Table 112. RadioMedix Competitive Strengths & Weaknesses
Table 113. Telix Pharmaceuticals Basic Information, Area Served and Competitors
Table 114. Telix Pharmaceuticals Major Business
Table 115. Telix Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
Table 116. Telix Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Telix Pharmaceuticals Recent Developments/Updates
Table 118. Telix Pharmaceuticals Competitive Strengths & Weaknesses
Table 119. Orano Med Basic Information, Area Served and Competitors
Table 120. Orano Med Major Business
Table 121. Orano Med Antibody-radionuclide Conjugates Product and Services
Table 122. Orano Med Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Orano Med Recent Developments/Updates
Table 124. Orano Med Competitive Strengths & Weaknesses
Table 125. Actinium Pharmaceuticals Basic Information, Area Served and Competitors
Table 126. Actinium Pharmaceuticals Major Business
Table 127. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
Table 128. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Actinium Pharmaceuticals Recent Developments/Updates
Table 130. Actinium Pharmaceuticals Competitive Strengths & Weaknesses
Table 131. Y-mAbs Therapeutics Basic Information, Area Served and Competitors
Table 132. Y-mAbs Therapeutics Major Business
Table 133. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product and Services
Table 134. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Y-mAbs Therapeutics Recent Developments/Updates
Table 136. Fusion Pharmaceuticals Basic Information, Area Served and Competitors
Table 137. Fusion Pharmaceuticals Major Business
Table 138. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product and Services
Table 139. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 140. Global Key Players of Antibody-radionuclide Conjugates Upstream (Raw Materials)
Table 141. Antibody-radionuclide Conjugates Typical Customers
LIST OF FIGURE
Figure 1. Antibody-radionuclide Conjugates Picture
Figure 2. World Antibody-radionuclide Conjugates Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Antibody-radionuclide Conjugates Total Market Size (2018-2029) & (USD Million)
Figure 4. World Antibody-radionuclide Conjugates Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Antibody-radionuclide Conjugates Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Antibody-radionuclide Conjugates Revenue (2018-2029) & (USD Million)
Figure 13. Antibody-radionuclide Conjugates Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 16. World Antibody-radionuclide Conjugates Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 18. China Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 23. India Antibody-radionuclide Conjugates Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Antibody-radionuclide Conjugates by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Antibody-radionuclide Conjugates Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Antibody-radionuclide Conjugates Markets in 2022
Figure 27. United States VS China: Antibody-radionuclide Conjugates Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Antibody-radionuclide Conjugates Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Antibody-radionuclide Conjugates Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Antibody-radionuclide Conjugates Market Size Market Share by Type in 2022
Figure 31. Beta-emitting
Figure 32. Targeted Alpha Therapy
Figure 33. World Antibody-radionuclide Conjugates Market Size Market Share by Type (2018-2029)
Figure 34. World Antibody-radionuclide Conjugates Market Size ??, (USD Million), 2018 & 2022 & 2029
Figure 35. World Antibody-radionuclide Conjugates Market Size Market Share ?? in 2022
Figure 36. Solid Tumor
Figure 37. Non Hodgkin Lymphoma
Figure 38. Antibody-radionuclide Conjugates Industrial Chain
Figure 39. Methodology
Figure 40. Research Process and Data Source
